Integer Holdings Corp

  • Health Care
  • Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • www.integer.net
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $4.64B
  • PE 41
  • Debt $1.10B
  • Cash $35.57M
  • EV $5.70B
  • FCF $74.24M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$113.55M
EBIT$194.72M
ROE7%
ROA6%
FCF$74.24M
Equity$1.62B
Growth Stability70%
PE40.85
PEG61.8
PB2.86
P/FCF62.48
P/S2.76
Price/Cash0.01
Debt/Equity0.68
Debt/FCF14.76
Net Margins7%
Gross Margins27%
Op. Margins12%
Earnings CAGR8%
Sales Growth YoY3%
Sales Growth QoQ-5%
Sales CAGR2%
FCF CAGR-5%
Equity CAGR10%
Earnings Stability0.1
Earnings Growth YoY30%
Earnings Growth QoQ13%
Earnings CAGR 5Y1%
Sales CAGR 5Y41%
FCF CAGR 5Y-21%
Equity CAGR 5Y7%
Earnings CAGR 3Y14%
Sales CAGR 3Y14%
FCF CAGR 3Y-1%
Equity CAGR 3Y7%
Market Cap$4.64B
Revenue$1.68B
Assets$3.17B
Total Debt$1.10B
Cash$35.57M
Shares Outstanding33.28M
EV5.7B
Earnings Score8%
Moat Score80%
Safety Score71%
Final Score53%
Working Capital507.63M
Current Ratio3.28
Gross Profit$452.47M
Shares Growth 3y0%
Equity Growth QoQ4%
Equity Growth YoY11%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Integer Holdings is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into two business segments based on the product type: medical and nonmedical. The medical segment uses the firm's technologies to produce components and finished medical devices, and it generates the vast majority of revenue. The company earns more than half of its revenue in the United States.

SEC Filings

Direct access to Integer Holdings Corp (ITGR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 27
    • 10-Q Jun 28
    • 10-Q Mar 29
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 29
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jul 01
    • 10-Q Apr 01

Sector Comparison

How does Integer Holdings Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Integer Holdings Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 8%
Stability 10%
loading chart...

Integer Holdings Corp Discounted Cash Flow

Fully customizable DCF calculator online for Integer Holdings Corp.

= $526M
012345678910TV
fcf$74M$70M$67M$63M$60M$57M$54M$51M$48M$46M$44M$436M
DCF$64M$55M$48M$41M$35M$30M$26M$23M$19M$17M$168M
Value$526M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years01/201512/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins8%-1%0%5%14%8%7%8%5%6%7%
ROA-0%4%5%7%7%5%5%4%6%6%
ROE--1%1%7%16%8%6%7%5%6%7%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years01/201512/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--55.6737.5616.077.877.275.728.1722.7916.1614.76
Debt over Equity0.322.12.431.840.910.740.60.620.670.640.68
Growth Stability---100%100%100%70%85%74%100%70%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years01/201512/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-16%73%5%-17%4%-15%14%13%16%41%
Earnings YoY growth--114%-178%1K%152%-43%-20%25%-31%37%1%
Equity YoY growth-39%-15%23%19%9%10%7%5%7%7%
FCF YoY growth--157%-246%118%20%-4%15%-23%-60%45%-21%